Trung Huynh
Stock Analyst at UBS
(4.79)
# 122
Out of 5,017 analysts
52
Total ratings
71.43%
Success rate
31.88%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Trung Huynh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JSPR Jasper Therapeutics | Maintains: Buy | $29 → $25 | $2.39 | +946.03% | 3 | Aug 15, 2025 | |
| INSM Insmed | Maintains: Buy | $133 → $140 | $162.31 | -13.75% | 7 | Aug 13, 2025 | |
| LLY Eli Lilly and Company | Maintains: Buy | $1,050 → $895 | $811.52 | +10.29% | 9 | Aug 8, 2025 | |
| AMGN Amgen | Maintains: Neutral | $326 → $317 | $294.34 | +7.70% | 6 | Aug 6, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Neutral | $560 → $584 | $562.37 | +3.85% | 4 | Jul 11, 2025 | |
| CLDX Celldex Therapeutics | Maintains: Buy | $44 → $38 | $26.66 | +42.54% | 2 | May 9, 2025 | |
| PFE Pfizer | Maintains: Neutral | $24 → $25 | $24.63 | +1.50% | 6 | Apr 30, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Neutral | $60 → $54 | $43.41 | +24.41% | 5 | Apr 11, 2025 | |
| CABA Cabaletta Bio | Maintains: Buy | $10 → $7 | $2.52 | +177.78% | 2 | Apr 1, 2025 | |
| KYTX Kyverna Therapeutics | Initiates: Buy | $13 | $7.02 | +85.32% | 1 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $170 → $175 | $187.84 | -6.84% | 2 | Jul 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $125 → $126 | $84.59 | +48.96% | 3 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $170 | $229.14 | -25.81% | 1 | Nov 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $9.50 | - | 1 | Mar 23, 2021 |
Jasper Therapeutics
Aug 15, 2025
Maintains: Buy
Price Target: $29 → $25
Current: $2.39
Upside: +946.03%
Insmed
Aug 13, 2025
Maintains: Buy
Price Target: $133 → $140
Current: $162.31
Upside: -13.75%
Eli Lilly and Company
Aug 8, 2025
Maintains: Buy
Price Target: $1,050 → $895
Current: $811.52
Upside: +10.29%
Amgen
Aug 6, 2025
Maintains: Neutral
Price Target: $326 → $317
Current: $294.34
Upside: +7.70%
Regeneron Pharmaceuticals
Jul 11, 2025
Maintains: Neutral
Price Target: $560 → $584
Current: $562.37
Upside: +3.85%
Celldex Therapeutics
May 9, 2025
Maintains: Buy
Price Target: $44 → $38
Current: $26.66
Upside: +42.54%
Pfizer
Apr 30, 2025
Maintains: Neutral
Price Target: $24 → $25
Current: $24.63
Upside: +1.50%
Bristol-Myers Squibb Company
Apr 11, 2025
Maintains: Neutral
Price Target: $60 → $54
Current: $43.41
Upside: +24.41%
Cabaletta Bio
Apr 1, 2025
Maintains: Buy
Price Target: $10 → $7
Current: $2.52
Upside: +177.78%
Kyverna Therapeutics
Oct 10, 2024
Initiates: Buy
Price Target: $13
Current: $7.02
Upside: +85.32%
Jul 21, 2023
Maintains: Neutral
Price Target: $170 → $175
Current: $187.84
Upside: -6.84%
Mar 7, 2023
Maintains: Outperform
Price Target: $125 → $126
Current: $84.59
Upside: +48.96%
Nov 18, 2022
Initiates: Outperform
Price Target: $170
Current: $229.14
Upside: -25.81%
Mar 23, 2021
Upgrades: Outperform
Price Target: n/a
Current: $9.50
Upside: -